AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

When used in radionuclide therapy, it means the molecules would kill the cancerous cells, and not the healthy ones. "This powerful strategy will enable researchers and the pharmaceutical industry ...

Radionuclide therapy delivered directly to an artery is safe and feasible for patients with advanced meningioma, according to new research published in the December issue of The Journal of Nuclear ...

The treatment of cancer involves different strategies, such as chemotherapy, surgery, radiation therapy and, most recently, targeted therapies, such as the use of radionuclide-based therapies employed ...

Vivos Inc. (OTCQB: RDGL) is pleased to report that the first five patients demonstrated the safety of RadioGel Precision ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.

Radionuclide therapy is changing dynamically. Monoclonal antibody therapies for non-Hodgkins lymphoma using iodine-131; or imaging with indium-111, followed with yttrium-90 for the therapy are the ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, has successfully completed an oversubscribed US$112 ...

Decommissioning, Decontamination, and Technique Development During nuclear decommissioning, radionuclide contaminated materials need to be accurately identified and sentenced for disposal as ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an ...

This underscores the importance of timely intervention in cases of radionuclide exposure. Further research explored the long-term effects of DTPA therapy, particularly through inhalation.

Clinical-stage radiopharmaceutical company AdvanCell has completed an oversubscribed Series C financing round of $US112 ...